- Home
- LRMR vs RWAY Comparison
LRMR vs RWAY Comparison
Compare LRMR & RWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRMR | RWAY |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.0M | 321.2M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | LRMR | RWAY |
|---|---|---|
| Price | $2.97 | $8.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $16.50 | $11.08 |
| AVG Volume (30 Days) | ★ 1.1M | 348.8K |
| Earning Date | 04-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 16.65% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.96 |
| P/E Ratio | ★ N/A | $5.70 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.61 | $8.20 |
| 52 Week High | $5.37 | $11.63 |
Technical Indicators
Market Signals| Indicator | LRMR | RWAY |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 26.69 |
| Support Level | $2.89 | $8.20 |
| Resistance Level | $3.12 | $8.98 |
| Average True Range (ATR) | 0.20 | 0.21 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 13.89 | 13.68 |
Price Performance
Historical ComparisonAbout LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About RWAY Runway Growth Finance Corp.
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States.